N-Zyme Biomedical is pleased to announce that the Japan Patent Office (JPO) has granted the Company a new patent covering the use of HIV protease inhibitors for the treatment of reflux disease.
N-Zyme Biomedical, a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with reflux disease, including gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR), has received patent approval for Japanese Patent No. 2022-563006, titled “Aerosolized Formulations of HIV Protease Inhibitors for the Treatment of Airway Reflux.”
The patent granted by the JPO strengthens N-Zyme’s intellectual property portfolio covering the use of fosamprenavir and darunavir for the treatment of reflux disease, underscoring the novelty and innovation driving the Company’s drug development programs.
“This patent marks an important milestone for N-Zyme. It reinforces the scientific innovation behind our pipeline and strengthens our ability to deliver transformative therapies for patients living with reflux disease.”
— Franco Vigile, Co-Founder and Chief Executive Officer, N-Zyme Biomedical
Enter your email to get the latest developments on N-Zyme, including our research, clinical trials and corporate reports.
